

Alejandro R. Chade, MD, FAHA

Bibliography

h-index: 46

i10-index: 82

Citations (as 08/24/2022): 5927

Full-length articles

1. Chade AR, Rodriguez-Porcel M, Grande J, Krier J, Lerman A, Romero JC, Napoli C, Lerman LO. Distinct renal injury in early atherosclerosis and renovascular disease. *Circulation*. 106: 1165-1171, 2002.
2. Chade AR, Rodriguez-Porcel M, Rippentrop S, Lerman A, Lerman LO. Angiotensin II AT1 receptor blockade improves renal perfusion in hypercholesterolemia. *American Journal of Hypertension*. 16 (2) 111-115, 2003.
3. Wilson S, Chade AR, Feldstein A, Sawamura T, Napoli C, Lerman A, Lerman LO. Lipid-lowering independent effects of simvastatin on the kidney in experimental hypercholesterolemia. *Nephrology Dialysis Transplantation*. 18(4):703-709, 2003.
4. Chade AR, Rodriguez-Porcel M, Grande JP, Zhu X, Sica V, Napoli C, Sawamura T, Textor, SC, Lerman A, Lerman LO. Mechanisms of renal structural alterations in combined hypercholesterolemia and renal artery stenosis. *Arteriosclerosis, Thrombosis and Vascular Biology*. 23(7):1295-1301, 2003.
5. De Nigris F, Sica V, Herrmann J, Condorelli G, Chade AR, Tajana G, Lerman A, Lerman LO, Napoli C. c-Myc oncoprotein: cell cycle-related events and new therapeutic challenges in cancer and cardiovascular diseases. *Cell Cycle*. 2(4):325-328, 2003.
6. Chade AR, Best P, Rodriguez-Porcel M, Herrmann J, Zhu X, Sawamura T, Napoli C, Lerman A, Lerman LO. Endothelin-1 receptor blockade prevents renal injury in experimental hypercholesterolemia. *Kidney International*. 64(3):962-969, 2003.
7. Chade AR, Rodriguez-Porcel M, Herrmann J, Zhu X, Lerman A, Lerman LO. Beneficial effects of antioxidant vitamins on the stenotic kidney. *Hypertension*. 42(4):605-612, 2003.
8. Rodriguez-Porcel M, Herrmann J, Chade AR, Krier JD, Breen J, Lerman A, Lerman LO. Long-term antioxidant intervention improves myocardial microvascular function in experimental hypertension. *Hypertension*. 43(2):493-498, 2004.
9. Chade AR, Rodriguez-Porcel M, Herrmann J, Zhu X, Grande JP, Napoli C, Lerman A, Lerman LO. Antioxidant intervention blunts renal injury in experimental renovascular disease. *Journal of the American Society of Nephrology*. 15(4):958-966, 2004.
10. Chade AR, Krier JD, Rodriguez-Porcel M, Breen J, McKusic M, Lerman A, Lerman LO. Comparison of acute and chronic antioxidant interventions in experimental renovascular disease. *American Journal of Physiology: Renal, Fluid and Electrolyte Physiology*. 286(6):F1079-1086, 2004.
11. Zhu X, Rodriguez-Porcel M, Bentley MD, Chade AR, Sica V, Napoli C, Caplice N, Ritman EL, Lerman A, Lerman LO. Antioxidant intervention attenuates myocardial neovascularization in hypercholesterolemia. *Circulation*. 109; 2109-2115, 2004.
12. Chade AR, Bentley MD, Zhu X, Rodriguez-Porcel M, Niemeyer S, Amores-Arriaga B, Napoli C, Ritman E, Lerman A, Lerman LO. Antioxidant intervention prevents renal neovascularization in

- hypercholesterolemic pigs. *Journal of the American Society of Nephrology*. 15(7); 1816-1825, 2004.
13. Zhu X, Chade AR, Rodriguez-Porcel M, Bentley MD, Ritman EL, Lerman A, Lerman LO. Cortical microvascular remodeling in the stenotic kidney: Role of increased oxidative stress. *Arteriosclerosis, Thrombosis and Vascular Biology*. 24:1854-1859, 2004.
 14. Herrmann J, Samee S, Chade AR, Rodriguez-Porcel M, Lerman LO, Lerman A. Differential effect of experimental hypertension and hypercholesterolemia on adventitial remodeling. *Arteriosclerosis, Thrombosis and Vascular Biology*. 25(2);447-453, 2005.
 15. Chade AR, Herrmann J, Zhu X, Krier J, Lerman A, Lerman LO. Effects of proteasome inhibition on the kidney in experimental hypercholesterolemia. *Journal of the American Society of Nephrology*. 16(4); 1005-1012, 2005.
 16. Chade AR, Lerman A, Lerman LO. Kidney in early atherosclerosis (Review). *Hypertension*. 45;1042-1049, 2005.
 17. Lerman LO, Chade AR, Sica V, Napoli C. Animal models of hypertension: An overview. *Journal of Laboratory and Clinical Medicine*. 146:160-173, 2005.
 18. Chade AR, Mushin O, Zhu X, Rodriguez-Porcel M, Textor S, Grande JP, Lerman A, Lerman LO. Pathways of renal fibrosis and modulation of matrix turnover in experimental hypercholesterolemia. *Hypertension*. 46:772-779, 2005.
 19. Chade AR, Brosh D, Lerman LO, Higano S, Lennon R, Lerman A. Mild renal insufficiency is associated with reduced coronary flow in patients with non-obstructive coronary artery disease. *Kidney International*. 69(2):266-71, 2006.
 20. Rodriguez-Porcel M, Zhu XY, Chade AR, Amores-Arriaga B, Caplice NM, Ritman EL, Lerman A, Lerman LO. Functional and structural remodeling of the myocardial microvasculature in early experimental hypertension. *Amer J Physiol-Heart Circ Physiol*. 290(3):H978-84, 2006.
 21. Daghini E, Chade AR, Krier J, Versari D, Lerman A, Lerman LO. Acute inhibition of endogenous xanthine-oxidase improves renal hemodynamics and function in early atherosclerosis. *American Journal of Physiology: Renal, Fluid and Electrolyte Physiology*. 290(3):R609-15, 2006.
 22. Napoli C, De Nigris F, Pignalosa O, Lerman A, Sica G, Fiorito C, Sica V, Chade AR, Lerman LO. In vivo veritas: Thrombosis mechanisms in animal models” *Scand J Clin Lab Invest*. 66(5):407-28, 2006.
 23. Chade AR, Zhu X, Mushin O, Napoli C, Lerman A, Lerman LO. Simvastatin promotes angiogenesis and prevents microvascular remodeling in the chronic renal ischemia. *FASEB J*. 20(10):1706-8, 2006.
 24. Misra S, Gordon JD, Fu AA, Glockner JF, Chade AR, Mandrekar J, Lerman LO, Mukhopadhyay D. The porcine remnant (ablation) kidney model. *Journal of Surgical Research*. 135(2):370-379, 2006.
 25. Zhu X, Daghini E, Chade AR, Rodriguez-Porcel M, Napoli C, Lerman A, Lerman LO. Role of oxidative stress in remodeling of the myocardial microcirculation in hypertension. *Arteriosclerosis, Thrombosis and Vascular Biology*. 26(8):1746-52, 2006.
 26. Lerman LO, Chade AR. Atherosclerotic process, renovascular disease and outcomes from bench to bedside. *Current Opinions in Nephrology and Hypertension*. 15(6):583-587, 2006.

27. Chade AR, Krier J, Textor S, Lerman A, Lerman LO. Endothelin-A receptor blockade improves renal microvascular architecture and function in experimental hypercholesterolemia. *Journal of the American Society of Nephrology*. 17(12):3394-3403, 2006.
28. Daghini E, Primak AN, Chade AR, Krier JD, Zhu XY, McCollough CH, Lerman LO. Assessment of renal hemodynamics and function using 64-slice multidetector CT: Comparison with EBCT.” *Radiology*. 243(2):405-12, 2007.
29. Zhu XY, Daghini E, Rodriguez-Porcel M, Chade AR, Napoli C, Lerman A, Lerman LO. Redox-Sensitive myocardial remodeling and dysfunction in swine diet-induced experimental hypercholesterolemia. *Atherosclerosis*. 193(1):62-69, 2007.
30. Galili O, Versari D, Sattler K, Olson M, McConnell J, Chade AR, Lerman LO, Lerman A. Early experimental obesity is associated with coronary endothelial dysfunction and oxidative stress. *Am J Physiol Heart and Circulatory Physiology*. 292(2):H904-11, 2007.
31. Daghini E, Primak AN, Chade AR, Zhu XY, Ritman EL, McCollough CH, Lerman LO. Evaluation of porcine myocardial microvascular permeability and fractional vascular volume using 64-slice helical CT. *Investigative Radiology*. 42(5):274-82, 2007.
32. Mannheim D, Versari D, Daghini E, Gossl M, Galili O, Chade AR, Rajkumar VS, Ritman EL, Lerman LO, Lerman A. Impaired myocardial perfusion reserve in experimental hypercholesterolemia is independent of myocardial neovascularization. *Am J Physiol Heart Circ Physiol*. 292(5):H2449-58, 2007.
33. Zhu XY, Daghini E, Chade AR, Lerman A, Lerman LO. Simvastatin Prevents Coronary microvascular remodeling and myocardial hypertrophy in normocholesterolemic hypertensive pigs. *Journal of the American Society of Nephrology*. 18(4):1209-17, 2007.
34. Zhu XY, Bentley MD, Chade AR, Ritman EL, Lerman A, Lerman LO. Early changes in coronary artery wall structure detected by micro computed tomography in experimental hypercholesterolemia. *Am J Physiol Heart Circ Physiol*. 293(3):H1997-2003, 2007.
35. Chade AR, Krier J, Galili O, Lerman A, Lerman LO. Role of renal cortical neovascularization in experimental hypercholesterolemia. *Hypertension*. 50(4):729-736, 2007.
36. Herrmann J, Saguner AM, Versari D, Peterson TE, Chade AR, Olson M, Lerman LO, Lerman A. Chronic proteasome inhibition contributes to coronary atherosclerosis. *Circulation Research*. 101(9):865-874, 2007.
37. Chade AR, Krier J, Lerman A, Lerman LO. Simvastatin abates development of renal fibrosis in experimental renovascular disease. *Journal of Hypertension*. 26(8); 1651–166, 2008.
38. Zhu XY, Daghin E, Chade AR, Lavi R, Napoli C, Lerman A, Lerman LO. Disparate effects of simvastatin on angiogenesis during hypoxia and inflammation. *Life Science*. 83(23-24):801-9, 2008.
39. Lerman LO, Chade AR. Angiogenesis in the kidney: A new therapeutic target? *Current Opinions in Nephrology and Hypertension*. 18:160–165, 2009.
40. Chade AR, Zhu XY, Lavi R, Krier J, Pislaru S, Simari R, Napoli C, Lerman A, Lerman LO. Endothelial

progenitor cells restore renal function in experimental renovascular disease. *Circulation*. 119:547-557, 2009.

41. Goessl M, Versari D, Chade AR, Lerman LO, Erbel R, Ritman EL. Low vasa vasorum densities correlate with inflammation and subintimal thickening - potential role in location-determination of atherogenesis. *Atherosclerosis*. 206(2) 362-368, 2009.
42. *Zhu XY, *Daghini E, Chade AR, Versari D, Krier JD, Textor KB, Lerman A, Lerman LO. Myocardial microvascular function during acute coronary artery stenosis: Effect of hypertension and hypercholesterolemia. *Cardiovascular Research*. 83(2) 371-380, 2009. (* Co-first authors).
43. Zhu X-Y, Chade AR, Krier JD, Daghini E, Lavi R, Guglielmotti A, Lerman A, Lerman LO. The chemokine monocyte chemoattractant protein-1 contributes to renal dysfunction in swine renovascular hypertension. *Journal of Hypertension*. 27(10) 2063-2073, 2009.
44. Lin J, Zhu XY, Chade AR, Jordan K, Lavi R, Daghini E, Gibson M, Guglielmotti A, Lerman A, Lerman LO. Monocyte chemoattractant protein-1 mediates myocardial microvascular dysfunction in swine renovascular hypertension. *Atherosclerosis, Thrombosis, Vascular Biology*. 29(11) 1810-1816, 2009.
45. Iliescu R, Fernandez S, Kelsen S, Maric C, Chade AR. Role of renal microcirculation in experimental renovascular disease. *Nephrology Dialysis Transplantation*. 25(4) 1079-87, 2010.
46. Iliescu R, Chade AR. Progressive renal vascular proliferation and injury in obese Zucker rats. *Microcirculation*. 17, 250-258, 2010.
47. *Lavi R, *Zhu XY, Chade AR, Lin J, Lerman A, Lerman LO. Simvastatin decreases endothelial progenitor cell apoptosis in the kidney of hypertensive hypercholesterolemic pigs. *Arterioscler Thromb Vasc Biol*. 30(5):976-83, 2010.
48. Chade AR, Zhu XY, Krier J, Jordan K, Textor S, Grande J, Lerman A, Lerman LO. Endothelial Progenitor cells homing and renal repair in experimental renovascular disease. *Stem Cells*. 28(6):1039-47, 2010.
49. Chade AR, Kelsen S. Renal microvascular disease determines the responses to revascularization in experimental renovascular disease. *Circulation-Cardiovascular Interventions*. 3(4):376-83, 2010. PMID: 3032938
50. Chade AR. Renovascular Disease, microcirculation and the progression of renal injury. *American Journal of Physiology: Regulatory, Integrative, and Comparative Physiology*. 300(4):R783-790, 2011.
51. Kelsen S, Hall JE, Chade AR. Endothelin-A receptor blockade slows the progression of renal injury in experimental renovascular disease. *American Journal of Physiology-Renal Physiology*. 301(1):F218-225, 2011.
52. Maric-Bilkan C, Flynn E, Chade AR. Microvascular disease precedes the decline in renal function in the streptozotocin-induced diabetic rat. *Am J Physiol Renal Physiol*. 302(3): F308-15, 2012.
53. Chade AR, Kelsen S. Reversal of renal dysfunction by targeted administration of VEGF into the stenotic kidney: A novel potential therapeutic approach. *American Journal of Physiology-Renal Physiology*. 302(3), F308-315, 2012.

54. Stanley JL, Andersson IJ, Hirt CJ, Moore L, Dilworth MR, Chade AR, Sibley CP, Davidge ST, Baker PN. Effect of the anti-oxidant tempol on fetal growth in a mouse model of fetal growth restriction. *Biology of Reproduction*, 26;87(1):25, 1-8, 2012.
55. Kelsen S, He X, Chade AR. Early superoxide scavenging accelerates renal microvascular rarefaction and damage in the stenotic kidney. *American Journal of Physiology-Renal Physiology*, 15;303(4):F576-83, 2012.
56. Chade AR: "Renal Vascular Structure and Rarefaction" (Invited overview). *Compr Physiol*. Apr;3(2):817-31, 2013.
57. Stewart N, Chade AR: "Renoprotective Effects of Hepatocyte Growth Factor in the Stenotic Kidney". *Am J Physiol Renal Physiol*. 2013 Mar 15;304(6):F625-33.
58. Chade AR, Stewart N: "Angiogenic Cytokines in renovascular disease: Do they have potential for therapeutic use?" *J Am Soc Hypertens*. 2013 Mar;7(2):180-90.
59. Eirin A., Zhu XY, Li Z, Ebrahimi B, Zhang X, Tang H, Korsmo M, Chade AR, Grande JP, Lerman A, Textor S, Lerman, LO: "Endothelial progenitor cells induce macrophage phenotypic switch and improve renal recovery capacity in swine renal artery stenosis". *Arterioscler Thromb Vasc Biol*. 2013 May;33(5):1006-13.
60. Herrmann J, Wohler C, Saguner A, Flores A, Nesbitt L.; Chade AR, Lerman LO, Lerman A: "Primary Proteasome Inhibition Results in Cardiac Dysfunction". *Eur J Heart Fail*. Apr 24th, 2013
61. Flynn E, Lee J, Hutchens ZM, Chade AR, Maric-Bilkan C: "C-peptide preserves the renal microvasculature architecture in the streptozotocin-induced diabetic rat". *Journal of Diabetes and Complications*, 27(6):538-47, 2013.
62. Chade AR, Stewart NJ, Peavy PR: "Disparate effects of single endothelin A and B receptor blocker therapy on the progression of renal injury in advanced renovascular disease". *Kidney Int*. 85(4):833-44, 2014.
63. Chade AR, Tullos NA, Stewart NJ, Surles BL: "Endothelin-A Receptor Antagonism Following Renal Angioplasty Enhances Renal Recovery in Renovascular Disease". *Journal of the American Society of Nephrology*, 26(5):1071-80, 2015 (**Selected for press release**).
64. Wang X, Johnson AC, White T, Williams JM, Chade AR, Solberg-Woods L, Lee J, Kyle PB, Garrett MR: "Nephron Deficiency and Predisposition to Renal Injury in a Novel One-Kidney Rat Model". *Journal of the American Society of Nephrology*, 26 (7):1634-46, 2015.
65. Tullos NA, Stewart NJ, Davidovich R, Chade AR: "Chronic Blockade of Endothelin A and B Receptors using Macitentan in Experimental Renovascular Disease". *Nephrology, Dialysis, Transplantation*, 30(4):584-93, 2015.
66. Chade AR, Tullos NA, Harvey TW, Mahdi F, Bidwell GL: "Renal Therapeutic Angiogenesis Using a Bioengineered Polymer-stabilized VEGF Construct" *Journal of the American Society of Nephrology*, 27(6):1741-52, 2016 (**Selected for press release**).
67. Harvey TW, Engel, JE, Chade AR: "VEGF and Podocyte Protection in Chronic Hypoxia: Effect of Endothelin-A Receptor Antagonism". *Am J Nephrol*. 43(2):74-84, 2016.

68. Chade AR and Hall JE: "Role of the Renal Microcirculation in Progression of Chronic Kidney Injury in Obesity". *Am J Nephrol.*;44(5):354-367, 2016.
69. Bidwell GL, Reese C, Mahdi F, Shao Q, Chade AR: "A Peptide-targeted Biopolymer for Kidney Selective Drug Delivery" *American Journal of Physiology-Renal Physiology*, 312(1): F54-F64, 2017.
70. Chade AR: "Small Vessels, Big Role: Renal Microcirculation and Progression of Renal Injury". *Hypertension*. 69(4):551-563, 2017.
71. Drummond H, Zhang L, Chade AR, Hester R: "ASIC1a opposes vascular conductance to maximal exercise capacity and electrical muscle contraction". *Physiological Reports*, 2017 Aug;5(15).
72. Chade AR, Williams ML, Guise E, Vincent LJ, Harvey TW, Kuna M, Mahdi F, Bidwell GL: "Systemic biopolymer-delivered vascular endothelial growth factor promotes therapeutic angiogenesis in experimental renovascular disease". *Kidney International*, 93, 842-854, 2018.
73. Guise E and Chade AR: "VEGF therapy for the kidney: emerging strategies" *American Journal of Physiology-Renal Physiology*, 315(4):F747-F751, 2018.
74. Kuna M, Mahdi F, Chade AR, Bidwell GL: "Molecular Size Modulates Pharmacokinetics, Biodistribution, and Renal Deposition of the Drug Delivery Biopolymer Elastin-like Polypeptide". *Sci Rep*. 8(1):7923. 2018.
75. Chade AR, Williams ML, Engel JE, Guise E, Harvey TW: "A Translational Model of Chronic Kidney Disease in Swine". *American Journal of Physiology-Renal Physiology*, 315(2): F364-F373, 2018.
76. Chade AR: "Understanding and managing atherosclerotic renovascular disease: Still a work in progress". *F1000 Faculty Research-Review*, Nov 29;7. 2018.
77. Lerman LO, Kurtz TW, Touyz RM, Ellison DH, Chade AR, Crowley SD, Mattson DL, Mullins JJ, Osborn J, Eirin A, Reckelhoff JF, Iadecola C, Coffman TM: "AHA Scientific Statement: Animal Models of Hypertension-A Scientific Statement from the American Heart Association". *Hypertension*. 73(6):e87-e120. 2019.
78. Guise E, Engel JE, Williams ML, Mahdi F, Bidwell GL, Chade AR: "Biopolymer-derived Vascular endothelial Growth Factor Improves Renal Outcomes Following Revascularization". *Am J Physiol Renal Physiol*. 1;316(5):F1016-F1025. 2019.
79. Engel JE, Williams E, Williams ML, Bidwell GL, Chade AR: "Targeted VEGF therapy induces long-term renal recovery in chronic kidney disease via macrophage polarization ". *Hypertension*. 74(5):1113-1123. 2019. **(Selected as High Impact Paper-Basic Science 2019)**
80. Engel JE and Chade AR: " Macrophage polarization in chronic kidney disease: a balancing act between renal recovery or decline?" *Am J Physiol Renal Physiol*. 317(6):F1409-F1413. 2019.
81. Mahdi F, Chade AR, Bidwell GL: "Utilizing a Kidney Targeting Peptide to Improve Renal Deposition of a Pro-angiogenic Protein Biopolymer" *Pharmaceutics*, 11(10). 2019.
82. Guise E and Chade AR: "A validated Boolean model of Microvascular Rarefaction to Predict Treatment Outcomes in Rena; Disease" *Sci Rep*. 2020 Jan 16;10(1):440.

83. Spradley FT, Ge Y, Chade AR: "Utero-placental vascular remodeling during late gestation in Sprague-Dawley rats " *Pregnancy Hypertens*, 20:36-43. 2020.
84. Chade AR, Williams ML, Engel JE, Williams E, Bidwell GL: "Molecular Targeting of Renal Inflammation using Drug Delivery Technology to Inhibit NF-kB Improves Renal Recovery in Chronic Kidney Disease" *Am J Physiol Renal Physiol*. 319(1):F139-F148. 2020.
85. Dalmaso C, Chade AR, Bix GJ, Mendez M, Chen KC, Loria AS: "Reduction of Intrarenal Angiotensin II Levels in Response to Early Life Stress is Associated with Increased Microvascular Density" *Front Physiol*. 11:1046, 2020.
86. Engel JE, Williams ML, Williams E, Azar C, Taylor ER, Bidwell GL, Chade AR: " Recovery of Renal Function Following Kidney Specific VEGF Therapy in Experimental Renovascular Disease". *American Journal of Nephrology*,51(11):891-902, 2020.
87. Waller JP, Burke S, Engel JE, Chade AR, and Gene L. Bidwell, III: "Dose-Escalating Toxicology of the Candidate Biologic ELP-VEGF". *Scientific Reports* 11, 6216. 2021.
88. Tucci M, Pride Y, Sereduck S, Salazar-Marochio S, Jackson R, Jefferson JR, Chade AR, Grill RJ, Grayson BE: "Delayed systemic treatment with cannabinoid receptor 2 agonist mitigates spinal cord injury-induced osteoporosis more than treatment directly following injury". *Neurotrama Reports*, 2(1):270-284, 2021.
89. Chade AR, Engel J, Hall ME, Eirin, A, Bidwell GL: "Intra-renal Modulation of NF-kB Activity Attenuates Cardiac Injury in a Swine Model of CKD: A Renal-Cardio Axis". *Am J Physiol Renal Physiol* 321: F411–F423, 2021.
90. Farahani RA, Yu S, Ferguson CM, Zhu YX, Tang H, Jordan KL, Saadiq IM, Chade AR, Lerman A, Lerman LO, Eirin A: "Renal revascularization attenuates myocardial mitochondrial damage and improves diastolic function in pigs". *J Cardiovasc Transl Res*. 2022 Feb;15(1):15-26.
91. Irazabal MV, Chade AR, Eirin, A: "Chronic renal injury and metabolic derangements: role of mtDNA and mitomiRs". *Clin Sci (Lond)*. 2022 Mar 18;136(5):345-36 (Invited review).
92. Chade AR and Bidwell GL: "Novel Drug Delivery Technologies and Targets for Renal Disease". *Hypertension*. 79(9):1937-1948, 2022.
93. Rajagopalan KS, Glasstetter LM, Zhy XY, Thaler R, Tang H, Jordan KL, Saadiq IM, Herrmann SM, Chade AR, Irazabal MV, Lerman LO, Eirin, A: "Renal ischemia induces epigenetic changes in apoptotic, proteolytic, and mitochondrial genes in swine scattered tubular-like cells". *Cells*. 2022 May 31;11(11):1803.
94. Chade AR, Eirin, A: "Cardiac micro-RNA and transcriptomic profile of a novel swine model of chronic kidney disease and left ventricular diastolic dysfunction (CKD-LVDD)". *Am J Physiol- Heart and Circulatory Physiology*, 2022 (In press).
95. Eirin, A, Chade AR: "Cardiac epigenetic changes in VEGF signaling genes associates with myocardial microvascular rarefaction in experimental chronic kidney disease". *Journal of Cardiac Failure*, 2022 (In review).

96. Rajagopalan KS, Kazemina S, Glasstetter LM, Farahani RA, Zhy XY, Tang H, Jordan KL, Chade AR, Lerman A, Lerman LO, Eirin, A: "Metabolic syndrome induces epigenetic alterations in mitochondria-related genes in swine mesenchymal stem cells". *Stem Cell reviews and Report*, 2022 (In review).

Book chapters/edited:

1. Chade AR: "Microvascular Disease". Chapter 9 in *Renal Vascular Disease*, edited by Lilach O. Lerman and Stephen C. Textor. Springer Verlag, London, 2014. *Contributor*
2. "Studies on Atherosclerosis: Oxidative Stress in Applied Basic Research and Clinical Practice". *Editors: Rodriguez-Porcel M, Chade AR, and Miller JD. Springer. 2016*
3. "Physiology Review"- Company of "Guyton and Hall-Textbook of Medical Physiology, 14th edition". *Contributor*

Invited comments and Editorials

1. Chade AR, Lerman A, and Lerman LO: "Atherosclerotic renovascular disease: Beyond the obstruction". International Atherosclerosis Society. Published on-line (<http://www.athero.org>). August, 2003.
2. Chade AR: "Atherosclerotic renovascular disease: Problems beyond the obstruction". *Kidney International*, 70;830-832, 2006.
3. Chade AR and Lerman LO: "The kidney in atherosclerosis: role of the endothelin system" International Atherosclerosis Society. Published on-line (<http://www.athero.org>). January, 2007.
4. Chade AR: "VEGF: Potential therapy for renal regeneration". *F100 Reports*, 4(1), 2012.
5. Chade AR: "VEGF therapy for the kidney: Are we there yet?" *J Am Soc Nephrol*. (1):1-3. 2016.

Abstracts

1. Chade AR, Best P, Rodriguez-Porcel M, Sawamura T, Lerman, A, Lerman LO. Endothelin-A receptor blockade improves renal hemodynamics and function in experimental hypercholesterolemia. *Hypertension*. 40(3) 429, 2002.
2. Chade AR, Rodriguez-Porcel M, Grande JP, Napoli C, Sawamura T, Lerman A, Lerman LO. Concurrent hypercholesterolemia and hypoperfusion augment pro-inflammatory changes in the stenotic kidney. *Hypertension*. 40(3) 419, 2002.
3. Chade AR, Rodriguez-Porcel M, Herrmann J, Zhu XC, Lerman A, Lerman LO. Chronic antioxidant vitamin supplementation improves renal hemodynamics in renal artery stenosis. Abstract book, page 74 (P54) of the XVth Scientific Meeting of the Inter-American Society of Hypertension, San Antonio, Texas, April 2003.
4. Chade AR, Rodriguez-Porcel M, Krier J, Lerman A, Lerman LO. Concurrent hypercholesterolemia and hypertension increase intra-renal pro-fibrotic activity. Abstract book, page 132 (P291) of the XVth Scientific Meeting of the Inter-American Society of Hypertension, San Antonio, Texas, April 2003.
5. Zhu X, Rodriguez-Porcel M, Bentley M, Chade AR, Ritman EL, Lerman A, Lerman LO. Antioxidant supplementation attenuates myocardial neovascularization in hypercholesterolemic pigs. Abstract book, page 45 (16) of the XVth Scientific Meeting of the Inter-American Society of Hypertension, San

Antonio, Texas, April 2003.

6. Chade AR, Herrmann J, Zhu XC, Lerman A, Lerman LO. Proteasome inhibitors improve renal hemodynamics and attenuate intra-renal inflammation in early atherosclerosis. *Hypertension*. 42(3) 441, 2003.
7. Chade AR, Rodriguez-Porcel M, Krier JD, Herrmann J, Zhu XC, Lerman A, Lerman LO. Chronic antioxidant intervention preserves microvascular structure in renal artery stenosis. *Hypertension*. 42(3) 393-394, 2003.
8. Zhu X, Chade AR, Rodriguez-Porcel M, Krier JD, Ritman EL, Lerman A, Lerman LO. Chronic antioxidant intervention preserves cortical microvascular structure in renal artery stenosis. Abstract book, page 81 (D298) of the Experimental Biology Meeting, Washington, D.C., April 2004. *FASEB on line*. Vol. 18, abstract #2576, 2004.
9. Krier JD, Chade AR, Lerman LO. Exacerbated oxidation of low density lipoprotein in concurrent hypercholesterolemia and hypertension. Abstract book, page 79 (D257) of the Experimental Biology Meeting, Washington, D.C., April 2004.
10. Chade AR, Mushin O, Rodriguez-Porcel M, Lerman A, Lerman LO. Reversal of diet improves renal hemodynamics and attenuates renal injury in early atherosclerosis. *Hypertension*. 44(3) 552-553, 2004.
11. Chade AR, Krier JD, Lerman A, Lerman LO. HMG Co-A Reductase inhibitors improve renal hemodynamics and function in renal ischemia. *Circulation*. 110(17), III-313 (Abstract 1499), 2004.
12. Zhu XY, Chade AR, Ritman EL, Lerman A, Lerman LO. Simvastatin preserves renal microvascular structure in renal artery stenosis. Abstract book, page 378A, (#1042-135) of the 54th Scientific Sessions of the American College of Cardiology, Orlando, FL, March 2005.
13. Zhu XY, Rodriguez-Porcel M, Chade AR, Ritman EL, Lerman A, Lerman LO. Coronary microvascular remodeling in hypertension: Role of oxidative stress. Abstract book, page 433A (#1157-131) of the 54th Scientific Sessions of the ACC, Orlando, FL, March 2005.
14. Chade AR, Zhu X, Lerman A, Lerman LO. HMG Co-A Reductase Inhibitors Improve Renal Endothelial Function in Atherosclerotic Renal Artery Stenosis. Abstract book of the XVI Scientific Meeting of the Inter-American Society of Hypertension, April 2005.
15. Zhu XY, Chade AR, Lerman A, Lerman LO. Simvastatin Prevents Coronary microvascular remodeling in hypertension. Abstract book of the XVI Scientific Meeting of the Inter-American Society of Hypertension, April 2005.
16. Daghini E, Primak A, Chade AR, Krier JD, Zhu X, McCoullough CH, Lerman LO. Measurements of renal hemodynamics and function using 64-slice multidetector CT: Comparison with EBCT. RSNA meeting, November 2005.
17. Herrmann J, Saguner A, Chade AR, Versari D, Olson M, Lerman LO, Lerman A. Proteasome inhibition - A new road to atherogenesis?" *J Am Coll Cardiol*. 2006;47 Suppl. A, 329A.
18. Herrmann J, Saguner A, Versari D, Chade AR, Olson M, Lerman LO, Lerman A. Coronary endothelial dysfunction as a consequence of chronic in-vivo proteasome inhibition? European Society of cardiology Meeting, 2006.

19. Daghini E, Chade AR, Zhu X, Versari D, Krier JD, Lerman A, Lerman LO. Synergistic effect of hypertension and hypercholesterolemia on myocardial microvascular permeability response to acute coronary artery stenosis. 60th Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure Research, San Antonio, TX, October 4-7, 2006.
20. Daghini E, Primak AN, Chade AR, Krier JD, Zhu X, McCollough CH, Lerman LO. Evaluation of myocardial microvascular permeability and fractional vascular volume using 64-slice helical CT. AHA Scientific Sessions 2006 in Chicago, Illinois, November 12-15.
21. Chade AR, Textor, S, Lerman A, Lerman LO. Endothelin-A receptor blockade improves renal microvascular architecture and function in experimental hypercholesterolemia. Presented at the American Society of Nephrology- Scientific Session, Renal Week, San Diego, CA, November 2006.
22. Chade AR, Lerman LO. Simvastatin attenuates epithelial-to-mesenchymal transdifferentiation and renal scarring in the ischemic kidney. Presented at the Inter-American Society of Hypertension XVIIth Scientific Sessions, May 2007.
23. Chade AR, Zhu XY, Krier J, Pislaru S, Simari R, Lerman A, Lerman LO. Intra-renal infusion of autologous progenitor cells improves the hemodynamics and function of the ischemic kidney. Presented at the Inter-American Society of Hypertension XVIIth Scientific Sessions, May 2007.
24. Chade AR, Krier, Lerman A, Lerman LO. Thalidomide decreases inflammation and improves renal endothelial function in experimental hypercholesterolemia. Presented at the Inter-American Society of Hypertension XVIIth Scientific Sessions, May 2007.
25. Zhu XY, Chade AR, Pislaru S, Simari R, Lerman A, Lerman LO. Early renovascular hypertension upregulates vegf expression in endothelial progenitor cells. Presented at the Inter-American Society of Hypertension XVIIth Scientific Sessions, May 2007.
26. Lavi R, Chade AR, Zhu XY, Krier J, Lerman A, Lerman LO. Simvastatin improves renal function and decreases fibrosis in pigs with combined hypertension and hypercholesterolemia. Presented at the Inter-American Society of Hypertension XVIIth Scientific Sessions, May 2007.
27. Lavi R, Primak A, Daghini E, Chade AR, Krier J, Zhu XY, McCollough C, Lerman LO. Feasibility of determining renal artery stenosis degree and function with 64-slice multi-detect computed tomography. Presented at the Inter-American Society of Hypertension XVIIth Scientific Sessions, May 2007.
28. Zhu XY, Chade AR, Krier J, Daghini E, Lavi R, Lerman A, Lerman LO. Inhibition of the chemokine monocyte chemoattractant protein-1 decreases recruitment of circulating fibrocytes to the stenotic porcine kidney in renovascular hypertension. *J Am Coll Cardiol.* 51(10):A314, 2008.
29. Iliescu R, Reckelhoff J, Chade AR. Obesity increases renal cortical neovascularization in Zucker rats. *Experimental Biology* 2008, April 2008 San Diego, CA (published in *The FASEB Journal*; 2008, 22:947.7).
30. Zhu XY, Chade AR, Krier J, Daghini E, Lavi R, Guglielmotti A , Lerman A, Lerman LO. Inhibition of the chemokine monocyte chemoattractant protein-1 improves endothelial function of porcine kidney in renovascular hypertension. 62th Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure Research, Atlanta, GA (Published in *Hypertension.* 52(4) e32-e131, 2008).

31. Zhu XY, Chade AR, Krier J, Jing Lin, Lavi R, Lerman A, Lerman LO. Endothelial progenitor cells improve renal function in experimental atherosclerotic renovascular disease. 62th Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure Research, Atlanta, GA (Published in *Hypertension*. 52(4) e32-e131, 2008).
32. Jing Lin, Zhu XY, Chade AR, Krier J, Daghini E, Lavi R, Guglielmotti A, Lerman A, Lerman LO. MCP-1 mediates myocardial microvascular dysfunction in swine renovascular hypertension. 62th Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure Research, Atlanta, GA (Published in *Hypertension*. 52(4) e32-e131, 2008).
33. Fernandez S, Iliescu, R, Chade AR. Renoprotective effects of exogenous VEGF in experimental renovascular disease. 62th Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure Research, Atlanta, GA (Published in *Hypertension*. 52(4) e32-e131, 2008).
34. Zhu X, Chade AR, Lin J, Krier JD, Lerman A, Lerman LO. Activation of the Xanthine oxidase pathway in experimental atherosclerotic renovascular disease is blunted by cell-based therapy. Renal Week 2008, Nov., Philadelphia, American Nephrology Society (*J Am Soc Nephrol*. 19: 2008, p 649A, SA-PO2395).
35. Iliescu R, Chade AR. Renal neovascularization in experimental obesity. Renal Week 2008, Nov., Philadelphia, American Society of Nephrology (*J Am Soc Nephrol*. 19: 2008, p 110A, SA-FC491).
36. Iliescu R, Chade AR. Microvascular Loss and Progression of Renal Injury in Renovascular Disease: Renoprotective Effects of VEGF. Presented at Experimental Biology 2009, April 2009, New Orleans, LA (Published in *FASEB J*. 2009 23:804.7).
37. Kelsen S, Chade AR. Endothelin-A receptor blockade preserves the renal microcirculation in experimental renovascular disease. 63rd Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure Research, Chicago, IL (*Hypertension*. 54(4) e70, 2009).
38. Maric C, Manigrasso MB, Marbury DC, Chade AR. Decrease in renal microvascular density precedes the decline in renal function in STZ-induced diabetic rats. Presented at Renal Week 2009, Oct., San Diego, CA, American Society of Nephrology.
39. Chade AR, Kelsen S, Fails F, Bailey J. Renal microvascular disease and the responses to renal revascularization. Presented at Experimental Biology 2010, Anaheim, CA.
40. Chade AR, Kelsen S, Fails F, Bailey J. Endothelin-A receptor blockade improves angiogenic signaling in the stenotic kidney. Presented at Experimental Biology 2010, Anaheim, CA.
41. Veerisetty SS, Kelsen S, Chade AR. Novel renoprotective effect of endothelin-A receptor blockade by up-regulation of hepatocyte growth factor in the stenotic kidney. 64th Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure Research, Washington, DC, 2010. *Hypertension*. 56(5) e160, 2010.
42. Chade AR. Intra-renal administration of VEGF: A potential therapeutic approach for renovascular disease. Presented at Experimental Biology 2011, Washington, DC (04/11/2011).
43. Maric C, Flynn E, Chade AR. Treatment with C-peptide slows the progression of diabetic renal disease in the streptozotocin (STZ)-induced diabetic rat. Presented at Experimental Biology 2011, Washington, DC (04/11/2011).

44. Chade AR: "Potential Mechanisms of VEGF-Induced Renoprotection in Renovascular Disease" page e39, Abstract HG02, Hypertension 2011, 58:e33-e1832011.
45. Chade AR. Endothelin-A receptor blockade in chronic renovascular disease: A novel therapeutic application. Abstract FR-OR234, J Am Soc Nephrol 22: 2011. American Society of Nephrology-Kidney Week 2011, Philadelphia, PA, 2011.
46. Chade AR. Intra-renal administration of hepatocyte-growth factor reversed microvascular functional rarefaction and decreased remodeling in the stenotic kidney. 66th Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure Research, Washington, DC, 2012.
47. Chade AR. Chronic Endothelin-A Receptor Blockade Improved the Responses to Renal Revascularization in Experimental Renovascular Disease. American Society of Nephrology-Kidney Week 2012, San Diego, CA, 2012.
48. Chade AR: Atrasentan Therapy Enhanced Recovery of Renal Function After Renal Angioplasty in Experimental Renovascular Disease. 50th ERA-EDTA Congress, Istanbul, Turkey, May 21st, 2013.
49. Chade AR, Stewart NJ: Renal angioplasty, endothelin receptor blockers, and recovery of renal function: A, not B. American Society of Nephrology-Kidney Week 2013, Atlanta, GA, November 2013.
50. Tullos NA, Davidovich R, Chade AR: Dual ETA/B receptor blockade therapy in renovascular disease. Experimental Biology 2014, San Diego, CA, April 2014.
51. Chade AR, Tullos NA, Surlis, BL: Endothelin-A Receptor Antagonism Following Renal Angioplasty Enhanced the Recovery of Renal Function by Decreasing Podocyte and Tubular Damage. 68th Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure Research, San Francisco, CA, 2014.
52. Chade AR, Bidwell GL: Administration of Elastin-like Polypeptide-VEGF in the Stenotic Kidney: a Novel Targeted Treatment to Recover Renal Function. American Society of Nephrology-Kidney Week 2014, Philadelphia, PA, November 2014.
53. Chade AR, Harvey TW: Potential Mechanisms of Renoprotection in the Stenotic Kidney After Endothelin-type A Receptor Antagonism: Podocytes, VEGF and sFlt-1. Experimental Biology 2015, Boston, MA, April 2015.
54. Chade AR, Harvey TW, Bidwell GL: Systemic Administration of a Biopolymer-delivered VEGF Improved Renal Hemodynamics and Microvascular Rarefaction in Renal Artery Stenosis. Experimental Biology 2015, Boston, MA, April 2015.
55. Bidwell GL, Chade AR: A kidney-targeted protein biopolymer drug delivery system. Experimental Biology 2015, Boston, MA, April 2015.
56. Chade AR, Bidwell GL: "Therapeutic Angiogenesis in Renal Artery Stenosis: Intra-renal Therapy Using a Biopolymer-delivered VEGF Construct Ameliorates Microvascular Damage and Renal Dysfunction". 52th ERA-EDTA, London, UK, May 2015.
57. Chade AR, Vincent LJ, Mahdi F, Shao Q, Bidwell GL,: A Novel Kidney-targeted Bioengineered Protein Carrier for Drug Delivery Binds to the Kidney Independent of the Species. Experimental

Biology 2016, San Diego, CA, April 2016.

58. Chade AR, Vincent LJ, Bidwell GL: “A Novel Biopolymer-Delivered VEGF for Therapeutic Angiogenesis in Renovascular Disease: Targeting the Kidney Via Systemic Administration”. 53th ERA-EDTA, Vienna, Austria, May 2016.
59. Chade AR, Guise E, Vincent LJ, Bidwell GL: “Angioplasty Combined with Intra-renal Administration of a Biopolymer-delivered VEGF Construct to Improve Renal Recovery: A New Therapeutic Strategy”. American Society of Nephrology-Kidney Week 2016, Chicago, IL, November 2016.
60. Guise E, Harvey T, Williams M, Chade AR: “A Biopolymer-delivered VEGF Construct Improves Kidney Recovery by Stimulating Pro-angiogenic Signaling and Renal Progenitor Cell Mobilization in Chronic Renovascular Disease”. Experimental Biology 2017, Chicago, IL, April 2017.
61. Warrington JP, Spradley FT, Chade AR, Ryan MJ, Granger JP, Drummond HA: “Altered Placental Vascular Remodeling in a Mouse Model of Reduced beta-ENaC”. Experimental Biology 2017, Chicago, IL, April 2017.
62. Chade AR, Guise E, Williams M, Harvey T: A novel swine model of chronic renal disease. 54th ERA-EDTA, Madrid, Spain, June 2017. *Nephrol Dial Transplant (2017) 32 (suppl_3): iii450*. DOI: <https://doi.org/10.1093/ndt/gfx162.MP068>
63. Chade AR, Guise E, Williams M, Harvey T, Bidwell, GL: “Reversal of renal dysfunction and injury by therapeutic angiogenesis in chronic renal disease: not everything is lost”. 54th ERA-EDTA, Madrid, Spain, June 2017. *Nephrol Dial Transplant (2017) 32 (suppl_3): iii42*. DOI: <https://doi.org/10.1093/ndt/gfx113.MO004>
64. Chade AR, Williams M, Bidwell GL: “Therapeutic angiogenesis in CKD”. American Society of Nephrology-Kidney Week 2017, New Orleans, LA, November 2017.
65. Kuna M, Mahdi F, McGowan JWD, Chade AR, Bidwell GL: “Pharmacokinetics and Intra-Renal Accumulation of the Drug Delivery Biopolymer Elastin-Like Polypeptide is Dependent on its Molecular Weight”. American Society of Nephrology-Kidney Week 2017, New Orleans, LA, November 2017.
66. Guise E, Pruett WA, Chade AR: “A Boolean Model of Microvascular Rarefaction to Predict Renal Outcomes in Renovascular Disease”. Experimental Biology 2018, San Diego, CA.
67. Engel JE, Williams ML, Guise E, Drummond H, Chade AR: “Translational Traits of a Swine Model of CKD: Inflammation”. Experimental Biology 2018, San Diego, CA.
68. Chade AR, Engel JE, Williams ML, Bidwell GL: “Therapeutic Angiogenesis Promotes Renal Recovery in CKD Partly by Shifting Macrophage Phenotype”. 55th ERA-EDTA, Copenhagen, Denmark, May 2018.
69. Grill R., Sereduck S., Pride Y., Chade AR: “Acute but Sustained Treatment with Cannabinoid Receptor-2 Agonist Preserves Hind Limb Bone Density in Mice after SCI”. Scientific Sessions of the Society for Neuroscience, San Diego, CA, November 2018.
70. Guise E, Engel JE, Williams ML, Bidwell GL, Chade AR: “Bioengineered VEGF therapy following renal angioplasty in renovascular disease: More and better microvessels”. Experimental Biology 2019,

Orlando, FL.

71. Engel JE, Guise E, Bidwell GL, Chade AR: “VEGF Therapy Shifts Macrophage Phenotype and Improves Renal Recovery in Chronic Kidney Disease”. Experimental Biology 2019, Orlando, FL.
72. Chade AR, Engel JE, Williams E, Bidwell GL: “Molecular Targeting of Renal Inflammation Using Drug-Delivery Technology in Chronic Kidney Disease”. 56th ERA-EDTA, Budapest, Hungary, June 2019.
73. Chade AR, Engel JE, Williams E, Bidwell GL: “A novel kidney-targeted bioengineered carrier for VEGF delivery in experimental renovascular disease: Proof of concept”. 56th ERA-EDTA, Budapest, Hungary, June 2019.
74. Chade AR, Engel JE, Williams E, Williams M, Howell J, Bidwell GL: “Anti-inflammatory therapy in chronic kidney disease using drug-delivery technology: mechanisms and effects of renal NFkB inhibition”. American Society of Nephrology-Kidney Week 2019, Washington, DC, November 2019.
75. Grayson B, Pride Y, Sereduck S, Chade AR, Grill R, Tucci M: “Systemic Treatment with Cannabinoid Receptor 2 Agonist to Treat Osteoporosis in a Rodent Model of SCI”. Experimental Biology 2020, San Diego, CA, April 4-7 2020.
76. Waller J, Burke S, Engel J, Chade AR, Bidwell GL: “Determining the effects of pro-angiogenic ELP-VEGF therapy on tumor growth and progression”. Experimental Biology 2020, San Diego, CA, April 4-7 2020.
77. Chade AR, Williams E, Engel JE, Hall M: “A novel model of heart failure with preserved ejection fraction”. 57th ERA-EDTA, Milan, Italy, June 2020.
78. Chade AR, Engel JE, Williams E, Bidwell GL: “Chronic kidney disease, inflammation, and heart failure with preserved ejection fraction: A renal-cardio axis?”. 57th ERA-EDTA, Milan, Italy, June 2020.
79. Bidwell GL, Waller J, Engel J, Chade AR: “Dose Escalating Toxicology Study of ELP-VEGF, a Novel Biologic for Renal Therapeutic Angiogenesis”. 57th ERA-EDTA, Milan, Italy, June 2020.
80. Chade AR, Williams E, Engel JE, Hall M: “A novel model of chronic kidney disease and heart failure with preserved ejection fraction”. American Society of Nephrology-Kidney Week 2020, Denver, CO, October 2020.
81. Chade AR, Hall M, Fortenberry D, Bossier D, Bidwell GL: “A Renal-Cardio Inflammatory Axis Mediates Cardiac Dysfunction in CKD via IL-33-ST2: A Novel Mechanism”. 58th ERA-EDTA, Berlin, Germany, June 2021.
82. Collett JA, Hyuk B, Ullah M, Mehotra P, Chade AR, Bidwell GL, Basile DP: “ELP-VEGF 121 improves renal function, decreases inflammation, and induces vascular protection from ischemia-reperfusion injury in mice”. American Society of Nephrology-Kidney Week 2021, San Diego, CA.
83. Chade AR, Mohamed TMA, Eirin A: “Cytokines of Kidney Origin are retained in the Heart and Induce Cardiac Injury in CKD: A Renal-cardio Axis”. American Society of Nephrology-Kidney Week 2021, San Diego, CA.

84. Farahani RA, Ferguson CM, Zhu X-Y, Tang H, Jordan KL, Saadiq IM, Herrmann SM, Chade AR, Lerman A, Lerman LO, Eirin A: “Renal revascularization attenuates myocardial mitochondrial damage and improves diastolic function in pigs with metabolic syndrome and renovascular hypertension”. American Society of Nephrology-Kidney Week 2021, San Diego, CA.
85. Chade AR, Eirin A, Bidwell GL:” Feasibility and Efficacy of Targeted Cardiac NF-kB Inhibition in Experimental Diastolic Dysfunction Using Drug-Delivery Technology: A Proof-of-Concept Study”. Scientific Sessions of the American Heart Association 2021, Boston, MA.
86. Chade AR, Eirin A:” HFpEF in CKD is Associated with Elevated TNF- α /IL-6 Inflammatory Signaling from the Kidney”. Experimental Biology 2022, Philadelphia, PA.
87. Chade AR, Mohamed TMA, Eirin A:” Renal inflammatory signaling alters cardiomyocyte kinetics and lead to HFpEF in CKD: A mechanistic proof of concept study”. Experimental Biology 2022, Philadelphia, PA.
88. Chade AR, Bidwell GL: “Systemic therapy with a single-dose kidney-targeted bioengineered VEGF construct improves stenotic kidney hemodynamics in experimental renovascular disease”. 59th ERA-EDTA, Paris, France, May 2022.
89. Chade AR, Mohamed TMA, Miller J, Abouleisa R, Ouand Q, Tang H, Saadiq I, Eirin A: “A novel CKD to HFpEF connection: inflammatory signaling, micro-RNAs, and NF-kB”. 59th ERA-EDTA, Paris, France, May 2022.
90. Chade AR, Eirin A: “Chronic kidney disease is associated with cardiac downregulation of vascular endothelial growth factor A (VEGFA) and development of diastolic dysfunction: epigenetics and microRNAs”. 59th ERA-EDTA, Paris, France, May 2022.